“an increasing trend”

REDD1 mRNA expression exhibited an increasing trend ( P = 0.0581) in myotubes electroporated with shControl ( Figure 6B ).

In LH-NO 3 - -treated WT mice, no significant changes in proteins associated with the nitrate/nitrite reductive pathway were detected in skeletal muscle ( Figures 9E, F ), while nNOS−/− mice treated with H-NO 3 - showed an increasing trend of XOR protein in skeletal muscle ( p = 0.0583, unpaired t -test) ( Figures 9A, B ).

Results Early chest tube removal was associated with a significantly higher risk of pericardial effusion (RR 1.85, p = 0.0105), while pleural effusion showed an increasing trend with marginally significant difference (RR 1.19, p = 0.0584).

There was an increasing trend from an initial level of 11.9 μg/L to 48.8 μg/L at 12 months in canned Sh+, albeit without a significant difference between the time points ( P ≥ 0.0587) (Fig.

Additionally, alanine aminotransferase (ALT) had an increasing trend ( p = 0.059) in the VC group.

However, there was an increasing trend towards MMR in the IM/HCQ arm, and the number of ‘successes’ was 20.8% higher with IM/HCQ at 24 months (1-sided p=0.059 2-sided p = 0.090).

Furthermore, an increasing trend of abundance of Akkermania and Victivallis was observed after RS intake compared to that at baseline ( p = 0.059 and p = 0.059, respectively).

Compared with that in the NC group, the risk of dementia was significantly increased in the LMCI group (HR = 8.812, p < 0.001) and showed an increasing trend in EMCI subjects (HR = 2.109, p = 0.059).

The percentage of BW and JL showed an increasing trend in treatments compared to those of control group ( p < 0.059) and ( p < 0.079), respectively.

In the IBS-D group, patients with a high PBA/SBA ratio had a significantly higher defecation frequency than those with a low PBA/SBA ratio (3.5 [2.5, 4.5] vs 3.0 [1.5, 3.5]; P = 0.038), along with an increasing trend of bowel habit dissatisfaction (70.0 [60.0, 72.5] vs 60.0 [45.0, 70.0]; P = 0.059] and abdominal pain severity (40.0 [30.0, 60.0] vs 30.0 [20.0, 50.0]; P = 0.077).

In HOT, T re exhibited an increasing trend during the recovery phase (REC) compared with the CC ( P = .059), and HR remained elevated compared with the resting state ( P < .05).

Total tissue increased ( P < 0.05) while there was an increasing trend in lean tissue mass ( P = 0.059) ( Table 2 ).

We observed an increasing trend in P ET O 2 in the SPR group after the PR program vs. at baseline that did not reach statistical significance (115.0 ± 7.0 vs. 108.7 ± 3.9, respectively, p = 0.059) ( Table 3 ).

Platelet aggregation Compared with the IR group, the clopidogrel + IR group had lower MaxAR-ADP (9.65 ± 5.60% vs 75.52 ± 14.99%, P < 0.05) and AveAR-ADP values (13.22 ± 5.81% vs 71.32 ± 16.66%, P < 0.05) and showed an increasing trend for MaxAT-ADP (447.67 ± 49.45 s vs 374.83 ± 67.81 s, P = 0.059); the TMAO + clopidogrel + IR group had lower MaxAR-ADP (35.05 + 24.93%, P < 0.05) and AveAR-ADP values (25.50 + 18.60%, P < 0.05).

In patients with granular type, dysmotility symptoms were prevalent (p=0.018), and diarrhea showed an increasing trend (p=0.059).

Although no significant differences in IL-6 levels between the HEP and LEP were observed in healthy individuals within our study, IL-6 levels in the MS group showed an increasing trend during the HEP ( p = 0.059), suggesting heightened inflammatory responses in metabolically compromised individuals.

The incidence rate of AFM showed an increasing trend over time; however, it showed marginal significance (p=0.0592).

Responding patients displayed an increasing trend of this parameter at T1, which was not statistically significant (p=0.06, Figure 5B ).

EAT-2 expression increased significantly in K562 and U266, and an increasing trend was observed in RPMI 8226 ( P =0.06) and MM.1S ( P =0.08) at 4 hr in the Elo-treated group.

An increasing trend of Aβ 1–42 /Aβ 1–40 ratio was observed in VGs 0.005 (CI: −0.001, 0.010, p = 0.06) compared to RMEs, however was not statistically significant. p-tau181 Plasma p-tau181 was significantly higher in the LOV group compared to RMEs (p < 0.01) ( Figure 1(b) ). p-tau181 was not found to be statistically significantly different between other PBDs and RME.

The remote patient management approach exhibited an increasing trend in BARC 2 bleeding events (36/1040, 3.5% vs 22/1046, 2.1%, P =.06) but demonstrated a reduction in BARC 3‐5 bleeding events (6/1040, 0.6% vs 16/1046, 1.6%, P =.03).

For extension, an increasing trend was noted (from 54.80° ± 10.58 to 59.87° ± 4.61; p = 0.06), although the difference did not reach statistical significance.

Although an increasing trend was observed, the overall difference among the subgroups was not statistically significant ( p = 0.06).

As shown in Figure 4 A, mitochondrial NADH dehydrogenase 1, complex I ( Nd1 ), mitochondrial NADH dehydrogenase 5, complex 1 ( Nd5 ), cytochrome b, complex III ( Cytb ), mitochondrial cytochrome c oxidase I, complex IV ( Cox1 ), and mitochondrial ATP synthase 6, complex V ( Atp6 ) all showed an increasing trend (i.e., Nd1 and Atp6 , P = 0.06), with significant increases in Cytb ( P = 0.04) and Cox1 ( P = 0.04).

However, there was an increasing trend in TYG in LA ewes (1,038±98.8 mg/dL) vs C ewes (828±128.4 mg/dL; Student’s t -test P =0.06); the values for PA sheep were intermediate (953.7±291.1 mg/dL; Figure 1L ).